CTI BioPharma Corp. (NASDAQ:CTIC) shares traded -1.78% lower at $5.51 on Wall Street last session.
CTIC stock price is now 1.85% away from the 50-day moving average and 2.85% away from the 200-day moving average. The market capitalization of the company currently stands at $698.01M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
With the price target of $13, SVB Leerink recently initiated with Outperform rating for CTI BioPharma Corp. (NASDAQ: CTIC). On September 01, 2022, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $13, while ‘Cowen’ rates the stock as ‘Outperform’.
In other news, Craig Adam R, President and CEO sold 188,304 shares of the company’s stock on Nov 10. The stock was sold for $1,130,703 at an average price of $6.00. Upon completion of the transaction, the President and CEO now directly owns 27,861 shares in the company, valued at $0.15 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 09, President and CEO Craig Adam R sold 53,996 shares of the business’s stock. A total of $324,056 was realized by selling the stock at an average price of $6.00. This leaves the insider owning 27,861 shares of the company worth $0.15 million. Insiders disposed of 1,067,909 shares of company stock worth roughly $5.88 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CTIC stock. A new stake in CTI BioPharma Corp. shares was purchased by DRIEHAUS CAPITAL MANAGEMENT LLC during the first quarter worth $9,001,000. SECTORAL ASSET MANAGEMENT INC invested $5,335,000 in shares of CTIC during the first quarter. In the first quarter, PERCEPTIVE ADVISORS LLC acquired a new stake in CTI BioPharma Corp. valued at approximately $4,051,000. ALTIUM CAPITAL MANAGEMENT LP acquired a new stake in CTIC for approximately $2,353,000. WALLEYE CAPITAL LLC purchased a new stake in CTIC valued at around $2,187,000 in the second quarter. In total, there are 168 active investors with 79.30% ownership of the company’s stock.
CTI BioPharma Corp. (NASDAQ: CTIC) opened at $5.61 on Tuesday. During the past 12 months, CTI BioPharma Corp. has had a low of $1.50 and a high of $7.80. The fifty day moving average price for CTIC is $5.41 and a two-hundred day moving average price translates $5.36 for the stock.
The latest earnings results from CTI BioPharma Corp. (NASDAQ: CTIC) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.21, missing analysts’ expectations of -$0.2 by -0.01. This compares to -$0.26 EPS in the same period last year. For the current quarter, analysts expect CTIC to generate $17.17M in revenue.
CTI BioPharma Corp.(CTIC) Company Profile
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Baxalta. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
